Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(2)
N/A(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07553468Not ApplicableCompleted

Stromal Vascular Cells for the Treatment of Diabetic Peripheral Neuropathy

Role: lead

NCT07259993Phase 1Completed

Knee Osteoarthritis With Stromal Vascular Fraction Cells

Role: lead

NCT06373809Early Phase 1Completed

Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy

Role: lead

NCT06304623Phase 1Completed

SVF for Treating Pulmonary Fibrosis Post COVID-19

Role: lead

All 4 trials loaded